Aptinyx's pain compound misses Phase II endpoint

Aptinyx Inc. (NASDAQ:APTX) said all three doses of NYX-2925 missed the primary endpoint in a Phase II trial to treat pain associated with diabetic peripheral neuropathy.

The primary endpoint measured mean change in average daily pain scores on the Numerical Rating Scale from baseline to week 4. The double-blind, U.S. trial enrolled 300 patients to receive placebo or once-daily 10, 50 or 200 mg oral NYX-2925 for four weeks...